Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Asgn (ASGN) Liabilities and Shareholders Equity (2016 - 2025)

Asgn's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $3.7 billion for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 7.83% year-over-year to $3.7 billion; the TTM value through Dec 2025 reached $11.1 billion, down 19.47%, while the annual FY2024 figure was $3.4 billion, 3.26% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $3.7 billion at Asgn, roughly flat from $3.7 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $3.7 billion in Q2 2025 and bottomed at $3.3 billion in Q1 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $3.5 billion (2023), against an average of $3.5 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity rose 12.92% in 2021 before it fell 4.11% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.5 billion in 2021, then rose by 2.37% to $3.6 billion in 2022, then decreased by 1.15% to $3.5 billion in 2023, then decreased by 3.26% to $3.4 billion in 2024, then rose by 7.91% to $3.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ASGN's Liabilities and Shareholders Equity are $3.7 billion (Q3 2025), $3.7 billion (Q2 2025), and $3.7 billion (Q1 2025).